PDL BiopharmaPDLI
13F holders, Q2 2025 (June 30)7holders
0new positions
0sold out
$0.15avg. 13F price*
At the end of Q2 2025, 7 institutions reported holding PDL Biopharma Inc. (PDLI) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Diversified Trust Co. ($26K), Rhumbline Advisers ($2K) and Financial Gravity Companies, Inc. ($3).
- Company
- PDL Biopharma Inc.
- CUSIP
- 69329Y104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 7 holders
| Diversified Trust Co. | 0.00% | No change | 11,029 | $26K |
| Rhumbline Advisers | 0.00% | No change | 612 | $2K |
| Financial Gravity Companies, Inc. | 0.00% | — | 33 | $3 |
| Hancock Whitney Corp. | 0.00% | No change | 128,396 | $0 |
| Westside Investment Management, Inc. | 0.00% | No change | 500 | $0 |
| Argent Trust Co | 0.00% | No change | 41,405 | $0 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 100 | $0 |
"% of holder's portfolio" is PDLI's weight in each manager's 13F, not the share of PDL Biopharma Inc. the manager owns.